First Horizon Advisors Inc. Raises Position in Kenvue Inc. (NYSE:KVUE)

First Horizon Advisors Inc. lifted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,047 shares of the company’s stock after purchasing an additional 580 shares during the period. First Horizon Advisors Inc.’s holdings in Kenvue were worth $535,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Grove Bank & Trust grew its stake in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in Kenvue in the 4th quarter valued at approximately $29,000. Fortitude Family Office LLC grew its stake in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in Kenvue in the 3rd quarter valued at approximately $35,000. Finally, Versant Capital Management Inc grew its stake in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after buying an additional 1,441 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on KVUE. Barclays reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Canaccord Genuity Group reduced their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Finally, Piper Sandler boosted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Stock Performance

NYSE KVUE opened at $23.33 on Tuesday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $44.72 billion, a P/E ratio of 44.01, a P/E/G ratio of 2.62 and a beta of 1.45. The company has a fifty day moving average of $21.33 and a 200-day moving average of $22.21.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.52%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.